Stem cell collection and transplant in myeloma patients following lenalidomide or bortezomib based induction therapy

Newer agents such as lenalidomide, an immunomodulatory drug and bortezomib, a proteasome inhibitor, have been introduced into myeloma front-line therapy, and are associated with improved rates and depth of response. Reports suggest a reduced capacity to collect adequate numbers of stem cells following lenalidomide based induction with GCSF only.